Clinical Trial Update: Expanded Access to Fosigotifator

View source ↗

Summary

Expanded Access to Fosigotifator by AbbVie is no longer available for Vanishing White Matter disease and Cree leukoencephalopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cree Leukoencephalopathy
• Vanishing White Matter Disease

Drugs mentioned

• Fosigotifator (ABBV-CLS-7262)

Snippet

Sponsor: AbbVie | Conditions: Vanishing White Matter, Cree Leukoencephalopathy | Status: NO_LONGER_AVAILABLE